Eli Lilly and Company and Bristol-Myers Squibb Company: A Detailed Gross Profit Analysis

Eli Lilly vs. Bristol-Myers: A Decade of Profit Growth

__timestampBristol-Myers Squibb CompanyEli Lilly and Company
Wednesday, January 1, 20141194700000014683100000
Thursday, January 1, 20151265100000014921500000
Friday, January 1, 20161448100000015567200000
Sunday, January 1, 20171471000000016801100000
Monday, January 1, 20181601400000016811600000
Tuesday, January 1, 20191806700000017598300000
Wednesday, January 1, 20203074500000019056500000
Friday, January 1, 20213644500000021005600000
Saturday, January 1, 20223602200000021911600000
Sunday, January 1, 20233431300000027041900000
Monday, January 1, 20243635100000036624400001
Loading chart...

Data in motion

A Tale of Two Giants: Eli Lilly and Bristol-Myers Squibb

In the ever-evolving pharmaceutical industry, Eli Lilly and Bristol-Myers Squibb have consistently demonstrated their prowess. From 2014 to 2023, these two titans have shown remarkable growth in gross profit, reflecting their strategic innovations and market adaptability.

Eli Lilly's Steady Ascent

Eli Lilly's gross profit surged by approximately 84% over the decade, peaking in 2023. This growth underscores their successful product launches and expansion into emerging markets.

Bristol-Myers Squibb's Dynamic Growth

Bristol-Myers Squibb, on the other hand, experienced a dramatic 187% increase in gross profit, with a notable spike in 2020. This leap can be attributed to their strategic acquisitions and robust pipeline of new therapies.

Both companies have navigated challenges and capitalized on opportunities, setting benchmarks in the pharmaceutical sector. Their financial trajectories offer valuable insights into the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025